Foresight Acquisition Corp.

Roughly $44.9 million of the quarter's $97.8 million medical margin comes from payer settlements and prior-year development, which the company itself separates out; on the excluded basis the PMPM figure is $168 rather than $311. Membership is shrinking by design while revenue per member rises.

A going-concern question, a debt-covenant default risk and a state financial-solvency requirement appear in the same list — for a capitated-risk provider the solvency rule is a regulatory floor, not just an accounting one. Total share count is around 7.3 million across both classes. The financial statements are not in the portion read here.

Switching to payment-in-kind interest at 14% means no cash leaves the business, but the principal compounds at that rate for more than two years — the balance owed at September 2028 will be materially larger than today. Lenders accept PIK when a borrower cannot service cash interest, so this is a liquidity accommodation rather than a refinancing on better terms. For former FORE holders it is debt growing silently ahead of the equity while the maturity is pushed out.

A 1-for-50 reverse split in April 2025 followed by a Nasdaq 20% Rule vote on warrants tied to an unsecured promissory note is the signature of a company financing itself off the balance sheet at the shareholder's expense. Approval releases up to 3,341,130 new Class A shares against a post-split base already compressed fifty-fold, and rejection leaves the warrants unexercisable, which typically puts the underlying note financing in dispute.

A 1-for-50 reverse split in April 2025 tells you the post-de-SPAC equity had collapsed by roughly 98% before the adjustment, and FORE-legacy holders bear that in full with no trust to fall back on. The Nasdaq 5635(d) vote on 1,428,129 warrant shares is required because the issuance can exceed 20% of the Class A base, so approving it adds dilution on top — the price of the February 13, 2025 promissory-note financing the company needed.

Two conditions are stacked: an explicit going-concern doubt and a May 12, 2025 hard deadline on the second and final Nasdaq cure period. Missing that date means delisting, and the company says it must retain flexibility to access equity markets, which is a statement that dilution is coming. FORE-legacy holders have no trust floor, and Class V holders have no economic claim at all beyond a nominal $0.0001 per share.

What changed: Exhibit 99.1 to an 8-K of P3 Health Partners Inc. (Nasdaq: PIII): the August 10, 2026 press release reporting Q2 2026 results. At-risk membership was approximately 105,000, down 10% year over year, which the company attributes to previously disclosed intentional network and payer rationalization; total lives under management were about 133,000 including roughly 28,000 under management service arrangements. Total revenue was $386 million, up 9%, with total per-member capitated revenue up 15%. Why it matters: Roughly $44.9 million of the quarter's $97.8 million medical margin comes from payer settlements and prior-year development, which the company itself separates out; on the excluded basis the PMPM figure is $168 rather than $311. Membership is shrinking by design while revenue per member rises.

What changed: The 10-Q filed under Commission file number 001-40033 is that of P3 Health Partners Inc. (Nasdaq: PIII) for the quarter ended June 30, 2026, with 3,911,962 Class A and 3,349,020 Class V shares outstanding as of August 3, 2026. Why it matters: A going-concern question, a debt-covenant default risk and a state financial-solvency requirement appear in the same list — for a capitated-risk provider the solvency rule is a regulatory floor, not just an accounting one. Total share count is around 7.3 million across both classes. The financial statements are not in the portion read here.